Pennington Biomedical Research Center
Louisiana State University

13C-Acetate Magnetic Resonance Spectroscopy as a Diagnostic Test for Susceptibility to Hypoglycemia

Disclosure PBRC-2017-010

Description:

Exposure to severe hypoglycemia is associated with increased risk of cardia arrhythmias, sudden cardiac arrest, as well as serious neurological complications such as confusion, seizure, loss of consciousness, coma and brain death. These recurrent bouts of hypoglycemia in patients with diabetes often lead to the development of hypoglycemia associated autonomic failure (HAAF). These treatment induced hypoglycemic episodes are a significant impediment to the maintenance of healthy glucose level in individuals with diabetes. This technology is a novel biomarker that has a strong potential use as a clinical diagnostic test for assessing hypoglycemic risk in persons with diabetes.

Advantages:

- Non-invasive, low risk
- Useful for definitive diagnosis and severity of HAAF
- Remove reporting bias (ie., nocturnal hypoglycemia, unawareness, infrequent patient-physician encounters

Commercial Uses:

- Clinical diagnostic tool
- Research tool

Find PBRC Technologies:
http://businessdevelopment.pbrc.edu

6400 Perkins Road ○ Baton Rouge, LA ○ 70808

Inventor:

David McDougal, PhD
Neurobiology of Metabolic Dysfunction

Licensing Opportunities:

This technology is available for exclusive licensing

Additional development opportunities include funded research or joint venture

Status:

Subject of U.S.PCT Filed November 28, 2018

Contact:

Leslie Smith
225-763-2627
Leslie.Smith@pbrc.edu